Which ASX 200 share has quietly risen by almost 115% in 2023?

And it's resetting its 52-week high again today.

| More on:
Male building supervisor stands and smiles with his arms crossed at a building site with workers behind him.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

At the start of the year, plenty of brokers were recommending an ASX 200 share that has since risen by 114.3% and has just hit yet another 52-week high today.

That ASX 200 share is building materials supplier James Hardie Industries plc (ASX: JHX).

In early trading on Wednesday, the James Hardie share price is up 2.1% to $55.88. Meantime, the S&P/ASX 200 Index (ASX: XJO) is up 0.77% to 7,559 points.

In late 2022 and early 2023, a bunch of brokers including QVG Capital, L1 Capital, and Goldman Sachs were backing the stock to outperform in 2023.

They argued that the ASX 200 building materials share had been oversold due to the Australian and US housing market downturns in 2022, but remained attractive for long-term investing.

When James Hardie lowered its FY23 earnings guidance in February, top broker Citi said it was a "buying event" for investors.

If you'd listened to all this advice and put $10,000 into James Hardie on the first day of trading this year — when it closed at $26.12 per share — your holdings would now be worth a cool $21,368.

And James Hardie appears set to remain on a positive trajectory.

The ASX 200 share hit a new 52-week high in early trading this morning, reaching $56.05 apiece.

What do the experts think about this ASX 200 share today?

The consensus rating among the analysts on CommSec today is a moderate buy. The rating was reduced from a Strong Buy just a fortnight ago.

The latest analysis from Goldman Sachs describes the business as "outperforming the market without sacrificing margin". The broker has a buy rating on the stock and a 12-month target price of $54.45.

Goldman Sachs commented:

We increase our FY24e estimates by 14%, largely driven by an increase in expected North America earnings. This reflects a better volume outlook with associated operating leverage.

Based on guidance, the 3Q base was substantially better than we had forecast, and normal seasonality would suggest ~MSD+ sequential growth into the 4Q.

Our FY25/26 estimates have increased ~12%. As a result of our forecast changes, partially offset by a lower reference market multiple our TP increases to $54.45. Retain Buy.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bronwyn Allen has positions in James Hardie Industries Plc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Share Gainers

3 ASX 200 stocks storming higher in this week's sinking market

Investors have sent these three ASX 200 stocks soaring this week. But why?

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Gainers

Why 4DMedical, Develop Global, EOS, and Maas shares are racing higher today

These shares are ending the week on a high. But why?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 657% in a year, 4DMedcial shares rocketing another 20% today on big US news

ASX investors can’t get enough of 4DMedical shares today. Let’s see why.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 broke its losing streak to inch higher today.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Consumer Staples & Discretionary Shares

Bapcor shares soar 12% on the appointment of a new CEO

The market’s strong reaction reflects a clear message: investors are ready for a reset.

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Share Gainers

Why Bapcor, IDP Education, Netwealth, and Ora Banda shares are pushing higher today

These shares are catching the eye with solid gains on Thursday. But why are they rising?

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX stock is going parabolic, and I think it's still a buy

4DMedical shares are up nearly 500% in 2025, but improving revenue visibility suggests the growth story may not be over.

Read more »